

Hugo Horlings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9471089/publications.pdf>

Version: 2024-02-01

71
papers

16,654
citations

66234

42
h-index

76769

74
g-index

76
all docs

76
docs citations

76
times ranked

26945
citing authors

#	ARTICLE	IF	CITATIONS
1	Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. <i>British Journal of Cancer</i> , 2022, 127, 79-83.	2.9	5
2	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	3.2	4
3	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 56.	2.3	3
4	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 243-252.	1.3	27
5	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 316.	1.7	16
6	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	1.4	21
7	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547.	2.8	20
8	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	5.8	91
9	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021, 13, 4910.	1.7	8
10	IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. <i>Npj Breast Cancer</i> , 2021, 7, 138.	2.3	1
11	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
12	135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer. <i>Annals of Oncology</i> , 2020, 31, S61.	0.6	2
13	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	5.8	71
14	Prognostic factors in patients with oligometastatic breast cancer – A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 91, 102114.	3.4	24
15	Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa034.	0.1	13
16	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
17	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
18	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106

#	ARTICLE	IF	CITATIONS
19	Characteristics and Outcome of <i>AKT1</i> E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020, 10, 526-535.	7.7	36
20	The NF- κ B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. <i>Molecular Cancer Research</i> , 2020, 18, 1018-1027.	1.5	31
21	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. <i>Breast Cancer Research</i> , 2019, 21, 90.	2.2	81
22	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	15.2	589
23	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151.	2.2	30
24	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. <i>Cell</i> , 2019, 176, 775-789.e18.	13.5	760
25	Iatrogenic endometriosis harbors somatic cancer-driver mutations. <i>Human Reproduction</i> , 2019, 34, 69-78.	0.4	73
26	Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 649-659.	1.1	37
27	TERT promoter mutation in adult granulosa cell tumor of the ovary. <i>Modern Pathology</i> , 2018, 31, 1107-1115.	2.9	49
28	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i> -like status, tumor-infiltrating immune cells and survival. <i>Oncolmmunology</i> , 2018, 7, e1509820.	2.1	80
29	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.	9.4	220
30	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	13.9	451
31	Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 289-293.	0.9	32
32	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. <i>Nature</i> , 2017, 549, 106-110.	13.7	501
33	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	530
34	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
35	Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. <i>Oncotarget</i> , 2017, 8, 55582-55592.	0.8	9
36	Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. <i>BMC Cancer</i> , 2016, 16, 587.	1.1	26

#	ARTICLE	IF	CITATIONS
37	Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. <i>Oncotarget</i> , 2016, 7, 66970-66988.	0.8	58
38	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. <i>International Journal of Cancer</i> , 2015, 136, 1434-1444.	2.3	64
39	Using Somatic Mutations to Guide Treatment Decisions. <i>JAMA Oncology</i> , 2015, 1, 275.	3.4	15
40	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv428.	3.0	128
41	Retrospective analysis of metastatic behaviour of breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 547-557.	1.1	141
42	Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a low-grade serous tubal intra-epithelial carcinoma (STIC) on risk reducing surgery. <i>Gynecologic Oncology Reports</i> , 2015, 12, 72-74.	0.3	8
43	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. <i>Leukemia</i> , 2014, 28, 719-720.	3.3	91
44	Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. <i>Gynecologic Oncology</i> , 2014, 134, 498-504.	0.6	20
45	A case of meningoencephalitis by the relapsing fever spirochaete <i>Borrelia miyamotoi</i> in Europe. <i>Lancet</i> , The, 2013, 382, 658.	6.3	224
46	Genomic profiling of histological special types of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 257-269.	1.1	64
47	Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5139-5144.	3.3	150
48	High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. <i>Blood Cancer Journal</i> , 2013, 3, e139-e139.	2.8	164
49	Abrogation of BRAF ^{V600E} -induced senescence by PI3K pathway activation contributes to melanomagenesis. <i>Genes and Development</i> , 2012, 26, 1055-1069.	2.7	229
50	Integration of Clinical and Gene Expression Data Has a Synergetic Effect on Predicting Breast Cancer Outcome. <i>PLoS ONE</i> , 2012, 7, e40358.	1.1	35
51	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. <i>Nature Genetics</i> , 2011, 43, 621-629.	9.4	1,080
52	External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement. <i>PLoS ONE</i> , 2011, 6, e27446.	1.1	38
53	Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 725-736.	1.1	53
54	Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 599-608.	1.1	9

#	ARTICLE	IF	CITATIONS
55	MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing. <i>Cancer Research</i> , 2011, 71, 4443-4453.	0.4	331
56	Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. <i>Oncogene</i> , 2010, 29, 2013-2023.	2.6	385
57	Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. <i>Nature</i> , 2010, 464, 1071-1076.	13.7	4,648
58	Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2010, 16, 651-663.	3.2	61
59	Translating the Genomic Architecture of Breast Cancer into Clinical Applications. <i>Science Translational Medicine</i> , 2010, 2, 38ps32.	5.8	0
60	Left-sided native valve Staphylococcus aureus endocarditis. <i>Netherlands Journal of Medicine</i> , 2010, 68, 341-7.	0.6	4
61	Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7003-7011.	3.2	87
62	Recurrent fusion of <i>MYB</i> and <i>NFIB</i> transcription factor genes in carcinomas of the breast and head and neck. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18740-18744.	3.3	711
63	Molecular profiles of progesterone receptor loss in human breast tumors. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 287-299.	1.1	94
64	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 479-489.	1.1	124
65	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. <i>Modern Pathology</i> , 2009, 22, 1401-1414.	2.9	110
66	ESR1 gene amplification in breast cancer: a common phenomenon?. <i>Nature Genetics</i> , 2008, 40, 807-808.	9.4	53
67	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 6084-6091.	0.4	916
68	Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary. <i>Journal of Clinical Oncology</i> , 2008, 26, 4435-4441.	0.8	176
69	A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. <i>Cancer Cell</i> , 2007, 12, 395-402.	7.7	1,471
70	Genetic regulators of large-scale transcriptional signatures in cancer. <i>Nature Genetics</i> , 2006, 38, 421-430.	9.4	204
71	LUNG TUMOR LOCATION AND LYMPHOCYTE INFILTRATION IN MICE ARE GENETICALLY DETERMINED. <i>Experimental Lung Research</i> , 2005, 31, 513-525.	0.5	5